Abstract (163 words) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
induces coronavirus-19 disease (COVID-19) and is a major health concern. Following two …

The outbreak of the human coronavirus disease 2019 (COVID-19) has induced an
unprecedented increase in the use of several old and repurposed therapeutic drugs such as …

Background As the COVID-19 pandemic continues worldwide, severe COVID-19 outcomes
remain a major concern for patients with rheumatic and musculoskeletal diseases. We …

Abstract The Sputnik V COVID-19 vaccine is a member of the so-called vector vaccines and
uses two different vectors (Ad26 priming and Ad5 boost) to reduce the risk of a reduction in …

Lung alveolar type-II (AT-II) cells produce pulmonary surfactant (PS), consisting of proteins
and lipids. The lipids in PS are primarily responsible for reducing the air-fluid surface tension …

Pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced
COVID-19 implied the presence of excessive proinflammatory cytokines and chemokines in …

There is a possible role for oxidative stress, a state characterized by an altered balance
between the production of free radicals or reactive oxygen species (ROS) and antioxidant …

Several pre-clinical and clinical trials show that exogenous pulmonary surfactant has clinical
efficacy in inflammatory lung diseases, especially ARDS. By infecting type II alveolar cells …

The global scope and scale of the SARS-CoV-2 pandemic led to huge amounts of important
data from clinical observations and experimental analyses being collected, in particular …

Introduction Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019
(COVID-19) often leads to mortality. Outcomes of patients with COVID-19-related ARDS …